ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy 
Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential…
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
Company to host investor conference call and webcast today at 5:00 pm EST GAITHERSBURG, Md.,…
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology…
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
Eyenovia Reports Third Quarter 2020 Financial Results
Company to host conference call and webcast today, November 10, at 4:30pm ET NEW YORK,…
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian…
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected…
AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Histogen Reports Third Quarter 2020 Earnings and Provides Business Update
Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for…
ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage…
Osmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business Updates
Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”)…
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
– Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular…
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent…
Bioasis Announces Annual General Meeting Details
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF)…
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:…
10x Genomics Reports Third Quarter 2020 Financial Results
PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG) today reported…
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical…
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate…